Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of MEDI3250 versus placebo in healthy Japanese children and adolescents
2014-003400-70Phase 3
- Sponsor
- AstraZeneca
- Start
- Mar 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in influenza comparing MEDI3250 with Placebo (2 arms). Primary endpoint: Vaccine efficacy against matched wild-type influenza.
02
Drugs
live attenuated influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on 2014-003400-70.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003400-70.